Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive News A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHWritten by Nathan Reiff. Article Published: 2/12/2026. 
At a Glance - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
More than just a financial check-up, earnings for companies in the healthcare sector offer investors a key window into a firm's pipeline and development progress. Even well-established, stable firms in healthcare can surprise with growth after the release of a new blockbuster drug or medical device, and earnings periods give management an opportunity to provide context and commentary beyond regulatory notices like FDA approvals. When healthcare companies release earnings on the same day, it creates a busy stretch for investors trying to parse the noteworthy news and plan trades. On Feb. 10, 2025, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—all reported full-year and Q4 2025 results. Below are highlights and takeaways for healthcare investors looking to make an informed plan based on these updates. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance The Wall Street Journal is asking whether a stock market crash is coming. Research from Weiss Ratings suggests the first half of 2026 could be very tough for certain stocks as a radical shift hits the market. Some of America's most popular names could take serious damage. Analysts have identified five stocks you should consider avoiding before this event plays out. If these are in your portfolio, you'll want to review your positions carefully. See the five stocks to avoid and learn what's driving this shift. U.K.-based pharma giant AstraZeneca closed 2025 by cementing its position as a major cancer-medicine provider: oncology accounted for roughly 44% of product sales in the quarter. Sales of key oncology drugs such as Imfinzi and Enhertu rose as much as 48% year-over-year (YOY), helping drive total revenue growth of 8.6% to $58.7 billion for the period. After-tax profits surged alongside revenue, rising to $10.2 billion from $7 billion in the prior-year quarter, and the board declared a second interim dividend that is 7 cents higher per share than last year's. Investors also have a pipeline to watch: management said 20 Phase 3 readouts are expected in 2026, and the company reiterated guidance for solid increases in both total revenue and core earnings per share (EPS) for the full year. Following its strong results, AZN shares climbed nearly 3% in the hours after the report. Although 10 of 11 analysts rate AZN a Buy or equivalent, Wall Street remains mixed on valuation: the consensus price target of $95.75 implies roughly 51% downside from recent levels. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Watch Margins Edwards designs replacement heart valves and related surgical devices, plus monitoring systems. Its Q4 2025 results showed largely positive trends, including 13.3% YOY sales growth driven by transcatheter aortic valve replacement (TAVR) momentum and strong performance of the latest SAPIEN valve iteration. However, adjusted EPS missed analyst estimates, and gross profit margin declined by 0.8% YOY. Despite the mixed metrics, Edwards remains confident it will meet prior 2026 guidance of 8%–10% sales growth and EPS of $2.90 to $3.05. EW shares spiked above $80 in after-hours trading, about 4% higher than the prior close. Around two-thirds of analysts covering EW rate the stock a Buy, and the consensus implies roughly 25% upside to a target of $96.77. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Going Forward Zimmer Biomet, a maker of joint-replacement systems and implants, saw shares rise more than 3% hours after reporting EPS of $2.42—four cents above consensus—and revenue of $2.2 billion, up nearly 11% YOY and slightly ahead of expectations. Strong demand for orthopedic products helped drive both top- and bottom-line growth. The company is shifting focus toward the U.S., which represents close to 60% of its business, and continued utilization by insured patients should support near-term demand for Zimmer's products. Still, tariffs remain a headwind that could weigh on EPS and revenue in 2026. Management provided conservative guidance in the latest earnings report, forecasting adjusted EPS between $8.30 and $8.45 and free cash flow improvement of 8%–10%. Before the release, analysts were split on Zimmer: the company carries an overall Hold rating, according to MarketBeat, despite about 15% projected upside.
| 
